Publications by authors named "A Kadir Dokmeci"
Article Synopsis
- * Recent advancements in targeted therapy and immune-checkpoint inhibitors are now becoming available for treating unresectable HCC and preventing recurrence after curative procedures.
- * This clinical practice guideline aims to provide updated recommendations from Asia-Pacific experts on systemic therapy for HCC, addressing key questions about patient selection, effective treatments, and management strategies for immunotherapy.
Since the Asian Pacific Association for the Study of the Liver (APASL) published guidelines on non-cirrhotic portal fibrosis/idiopathic portal hypertension in 2007, there has been a surge in new information, especially with the introduction of the term porto-sinusoidal vascular disorder (PSVD). Non-cirrhotic intra-hepatic causes of portal hypertension include disorders with a clearly identifiable etiology, such as schistosomiasis, as well as disorders with an unclear etiology such as non-cirrhotic portal fibrosis (NCPF), also termed idiopathic portal hypertension (IPH). This entity is being increasingly recognized as being associated with systemic disease and drug therapy, especially cancer therapy.
View Article and Find Full Text PDFArticle Synopsis
- MAFLD (Metabolic Dysfunction-Associated Fatty Liver Disease) is becoming more common, and it can lead to serious liver problems called MAFLD-ACLF, but what affects patient recovery isn't fully known yet.
- In a study, researchers looked at data from patients with MAFLD-ACLF to understand their health conditions and see who survived after 90 days, finding that about 51% of patients did survive.
- They discovered new scoring systems to better predict survival, which included factors like diabetes and the causes of liver damage, and these new scores worked better than older ones.
Article Synopsis
- The study aimed to evaluate the relationship between ammonia levels and liver-related complications (LRCs) in patients with acute-on-chronic liver failure (ACLF).
- Higher ammonia levels were found in ACLF patients with LRCs, especially those experiencing overt hepatic encephalopathy (HE) and ascites, but not bacterial infections.
- Baseline arterial ammonia levels were identified as an independent predictor of 30-day mortality, but they did not predict the development of new LRCs within that timeframe.
Article Synopsis
- Acute-on-chronic liver failure (ACLF) significantly affects patients with alcoholic hepatitis (AH), with 38.8% mortality observed within 90 days.
- Research analyzed data from the AARC database, revealing a major portion of patients (82.8%) had ACLF, with corticosteroid treatment improving survival rates for nearly half of the steroid responders.
- The AARC score effectively predicts patient outcomes, indicating that those with ACLF grade 3 face higher risks of complications and may benefit from early liver transplantation.